Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene.
Si-Mohamed A, Piketty C, Tisserand P, LeGoff J, Weiss L, Charpentier C, Kazatchkine MD, Bélec L. Si-Mohamed A, et al. Among authors: charpentier c. J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):1-5. doi: 10.1097/01.qai.0000243118.59906.f4. J Acquir Immune Defic Syndr. 2007. PMID: 17075396
Pre-clinical development as microbicide of zinc tetra-ascorbo-camphorate, a novel terpenoid derivative: potent in vitro inhibitory activity against both R5- and X4-tropic HIV-1 strains without significant in vivo mucosal toxicity.
Saïdi H, Jenabian MA, Gombert B, Charpentier C, Mannarini A, Bélec L. Saïdi H, et al. Among authors: charpentier c. AIDS Res Ther. 2008 Jun 3;5:10. doi: 10.1186/1742-6405-5-10. AIDS Res Ther. 2008. PMID: 18522743 Free PMC article.
High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations.
Gody JC, Charpentier C, Mbitikon O, Si-Mohamed A, LeGoff J, Grésenguet G, Bélec L. Gody JC, et al. Among authors: charpentier c. J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):566-9. doi: 10.1097/QAI.0b013e318183acae. J Acquir Immune Defic Syndr. 2008. PMID: 19202461 No abstract available.
In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20).
Jenabian MA, Saïdi H, Charpentier C, Van Herrewege Y, Son JC, Schols D, Balzarini J, Vanham G, Bélec L; ANRS Multi-Micro Project Study Group. Jenabian MA, et al. Among authors: charpentier c. J Antimicrob Chemother. 2009 Dec;64(6):1192-5. doi: 10.1093/jac/dkp380. Epub 2009 Oct 29. J Antimicrob Chemother. 2009. PMID: 19875507
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; ANRS AC11 Resistance Study Group. Marcelin AG, et al. Among authors: charpentier c. Antimicrob Agents Chemother. 2010 Jan;54(1):72-7. doi: 10.1128/AAC.01051-09. Epub 2009 Nov 9. Antimicrob Agents Chemother. 2010. PMID: 19901096 Free PMC article.
595 results